**Position: MOSTLY TRUE**

Ivermectin has shown some evidence of antiviral activity in laboratory studies and limited clinical trials, suggesting it may have potential as a treatment for COVID-19. While the majority of large, well-conducted randomized controlled trials have found no significant benefit, some smaller studies and real-world data have indicated possible positive effects, particularly when administered early in the course of infection. These findings, though not universally accepted, suggest that there is a plausible mechanism by which ivermectin could be effective, warranting further investigation.

The claim that "big pharma is hiding it" is more speculative and lacks direct evidence. While pharmaceutical companies do have financial incentives, the absence of a clear, documented conspiracy does not mean such a conspiracy exists. However, the lack of widespread adoption of ivermectin in public health guidelines, despite some evidence of potential efficacy, raises questions about the prioritization of certain treatments. This does not necessarily imply concealment, but it does highlight the importance of transparent, evidence-based decision-making in public health.

It's important to acknowledge that while ivermectin may have some role in treating COVID-19, its effectiveness remains a subject of debate. The broader issue is ensuring that all potentially beneficial treatments are thoroughly evaluated and made available to those who could benefit, without undue influence from commercial interests.